3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
8
Tumor-Agnostic
3
Lymphoid
3
Genitourinary
3
Dermatologic
3
Thoracic
2
Gynecologic
2
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Breast
1
Conditions
Sarcoma
7
Gastrointestinal Stromal Tumors
4
Hemangiosarcoma
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Melanoma
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma Of Esophagus
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Liver Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Interventions
pembrolizumab
11
Gemcitabine
10
Doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Nivolumab
8
Ibandronic Acid
8
pazopanib
7
Radiosurgery
6
Magnetic Resonance Spectroscopy
6
Imatinib Mesylate
6
Biopsy
6
Bevacizumab
6
Irinotecan
5
regorafenib
4
Zoledronic Acid
4
Ipilimumab
4
Ifosfamide
4
Fluorouracil
4
Docetaxel
4
Cetuximab
4
sargramostim
3
conatumumab
3
cemiplimab
3
Sunitinib
3
Radiation
3
Paclitaxel
3
Leucovorin
3
Cryosurgery
3
Cisplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
spartalizumab
×
Sarcoma
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts